Which has the lower trailing P/E, DOCS or LGND?

LGND has the lower trailing P/E: DOCS trades at 33.77 and LGND at 31.97. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, DOCS or LGND?

Over the past five years, DOCS grew revenue faster — DOCS at a 21.94% CAGR versus LGND at 2.92%.

Is DOCS or LGND more profitable?

LGND runs the higher net margin — DOCS at 25.48% versus LGND at 67.88%.

How have DOCS and LGND total returns compared?

Over the past 5 years, DOCS delivered -18.23% and LGND delivered 30.72% annualized total return. Past performance doesn't predict future results.

Doximity, Inc. (DOCS) vs Ligand Pharmaceuticals Incorporated (LGND)

A side-by-side comparison of Doximity, Inc. and Ligand Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

DOCS

Doximity, Inc.

$5.37B

$28.71HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT

LGND

Ligand Pharmaceuticals Incorporated

$5.99B

$298.92HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

Total return — DOCS vs LGND

growth of $100 · dividends reinvested · last 5y

DOCS -46.1% (-11.6%/yr)LGND +288.4% (+31.2%/yr)LGND compounded faster over this window

Log scale — wide-divergence pair

DOCS LGND

DOCS vs LGND: by the numbers

•LGND is the larger company ($5.99B vs $5.37B market cap).
•LGND trades at the lower trailing earnings multiple (31.97 vs 33.77 P/E), one valuation lens rather than an overall verdict.
•LGND converts more revenue to profit (67.88% vs 25.48% net margin).
•DOCS grew revenue faster over the past five years (21.94% vs 2.92% CAGR).

Metrics side by side

Valuation

Metric	DOCS	LGND
P/E ratio	33.77	31.97
Forward P/E	21.31	32.12
PEG ratio	0.65	N/A
P/S ratio	8.19	20.62
P/B ratio	5.86	6.19
EV / EBITDA	24.12	45.31
FCF yield	5.57%	2.19%

Profitability

Metric	DOCS	LGND
Gross margin	88.07%	98.58%
Operating margin	29.60%	17.61%
Net margin	25.48%	67.88%
ROE	18.24%	20.38%
ROIC	15.35%	3.91%

Growth (annualized)

Metric	DOCS	LGND
Revenue CAGR (5Y)	21.94%	2.92%
EPS CAGR (5Y)	54.32%	N/A
FCF CAGR (5Y)	23.75%	-0.49%
Total return CAGR (5Y)	-18.23%	30.72%

Frequently asked

Which has the lower trailing P/E, DOCS or LGND?: LGND has the lower trailing P/E: DOCS trades at 33.77 and LGND at 31.97. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, DOCS or LGND?: Over the past five years, DOCS grew revenue faster — DOCS at a 21.94% CAGR versus LGND at 2.92%.
Is DOCS or LGND more profitable?: LGND runs the higher net margin — DOCS at 25.48% versus LGND at 67.88%.
How have DOCS and LGND total returns compared?: Over the past 5 years, DOCS delivered -18.23% and LGND delivered 30.72% annualized total return. Past performance doesn't predict future results.

Go deeper

Full DOCS analysis Full LGND analysis Interactive comparison tool

Dig into the metrics

Doximity P/E ratio Ligand Pharmaceuticals P/E ratio Doximity ROE Ligand Pharmaceuticals ROE Doximity operating margin Ligand Pharmaceuticals operating margin Doximity revenue growth Ligand Pharmaceuticals revenue growth Doximity free cash flow Ligand Pharmaceuticals free cash flow

Doximity & Ligand Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.